☆ 4.7 Article

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

CARDIOVASCULAR DIABETOLOGY (2021)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes -Systematic review and meta-analysis of randomized placebo-controlled trials

Husam M. Salah et al.

Summary: In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. The most significant risk reduction was seen in hospitalization for HF and progression of kidney disease, while the effects on mortality, MI, and stroke varied.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF

Pardeep S. Jhund et al.

Summary: The study found that dapagliflozin had consistent safety and efficacy in patients with heart failure and reduced ejection fraction regardless of kidney function status, and it could slow down the decline in eGFR. This effect was observed in patients with and without diabetes.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Dario Giugliano et al.

Summary: The review summarizes the progress in the treatment and prevention of cardiorenal complications in patients with T2D using SGLT-2 inhibitors, with a particular focus on age, the role of prevention, and the potential extension of their benefits.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis

Dario Giugliano et al.

Summary: This meta-analysis evaluates the cardiorenal outcomes of SGLT-2is in patients with type 2 diabetes, finding that SGLT-2is are associated with a reduced risk of major adverse cardiovascular events and significant benefits in the progression of diabetic kidney disease. There was no significant heterogeneity observed based on the presence or absence of cardiovascular disease in patients.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Empagliflozin and Major Renal Outcomes in Heart Failure

Milton Packer et al.

Summary: Empagliflozin had different effects on renal outcomes in heart failure patients between two trials, with major adverse renal outcomes occurring in 2.8% of patients who received the drug and 3.5% of those who received a placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction - A Win against a Formidable Foe

Mark H. Drazner

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials

Mei Qiu et al.

Summary: SGLT2is independently reduce heart failure composite outcome by 25%, showing greater efficacy in patients with NYHA class II and in Black and Asian patients.

CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects

Matthew Griffin et al.

CIRCULATION (2020)

Add to Collection

Article Endocrinology & Metabolism

Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression

Dario Giugliano et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Mark C. Petrie et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C Wheeler et al.

Lancet Diabetes & Endocrinology (2020)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects

Motoaki Sano et al.

CIRCULATION (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

Kenneth W. Mahaffey et al.

CIRCULATION (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

Vinay Garg et al.

PROGRESS IN CARDIOVASCULAR DISEASES (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Endocrinology & Metabolism

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials

Dario Giugliano et al.

ENDOCRINE (2019)

Add to Collection

Review Medicine, Research & Experimental

SGLT2 inhibition and kidney protection

Josselin Nespoux et al.

CLINICAL SCIENCE (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

SGLT2 inhibition and heart failure-current concepts

Joaquim Silva Custodio et al.

HEART FAILURE REVIEWS (2018)

Add to Collection

Article Endocrinology & Metabolism

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi et al.

DIABETES CARE (2018)

Add to Collection

Review Mathematical & Computational Biology

Comparative performance of heterogeneity variance estimators in meta-analysis: a review of simulation studies

Dean Langan et al.

RESEARCH SYNTHESIS METHODS (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Mathematical & Computational Biology

Basics of meta-analysis: I2 is not an absolute measure of heterogeneity

Michael Borenstein et al.

RESEARCH SYNTHESIS METHODS (2017)

Add to Collection

Article Endocrinology & Metabolism

CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis

Ele Ferrannini et al.

DIABETES CARE (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Pharmacology & Pharmacy

Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus

M. Pfister et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Medicine, General & Internal

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

Alessandro Liberati et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.